Skip to main content

NexgenRx: Top 10 Undervalued Healthcare Plans Industry Stocks (NXG)

AI-generated - The Globe and Mail - Mon May 5, 2025

NexgenRx is now ranked among the top 10 undervalued stocks in the Healthcare Plans industry on the Toronto Stock Exchange or TSX Venture Exchange.

  • A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
  • Valuation methodology provided by Stockcalc (see below)

Healthcare Plans: Companies that offer a wide variety of managed health products and services, including HMOs, PPOs, and other health insurance plans, and are largely U.S.-domiciled.

Stocks in this category are held primarily for capital appreciation.

SymbolNameClose Price ($)Valuation ($)DifferenceAverage Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
NXGNexgenRx0.290.300.01 (3.6%)394722.23.558.0

All data provided as of May 05, 2025.
The list is sorted by stocks with the greatest percentage difference between valuation and price.

NexgenRx

NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and provides ancillary services.

NexgenRx is listed under NXG on the TSX Venture Exchange.

Stockcalc

StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.

Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:

  • Discounted Cash Flow (DCF)
  • Price & Other Comparables
  • Multiples
  • Adjusted Book Value (ABV)
  • Analyst Consensus

Artificial Intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.